세계의 표면 소독제 시장 : 조성별, 유형별, 용도별, 최종사용자별, 지역별 - 예측(-2030년)

The global surface disinfectant market is projected to reach USD 4.38 billion by 2030 from USD 3.04 billion in 2025, at a CAGR of 7.6% during the forecast period.

This is due to the rising adoption of advanced surface disinfectants for sanitization, increasing surgical procedures, growing focus on infection control measures to mitigate hospital-acquired infections, and increasing consumer awareness of hygiene in healthcare settings. However, the potential consequences of chemical disinfectant use and the increasing adoption of alternative surface disinfection methods are the major restraints to the market. Additionally, the strict regulatory requirement landscape is a major challenge for market growth.

The surface disinfection segment accounted for the largest market share in 2024.

Based on application, the surface disinfectant market is segmented into surface disinfection, instrument disinfection, and other applications. The surface disinfection segment accounted for the larges market share in 2024. The large share of this application segment can be attributed to the high prevalence of hospital-acquired infections across the globe and the higher volume of disinfectants required to clean these surfaces. Areas such as hospital wards, operation theaters, reception areas, and clinics are home to a wide range of germs and bacteria, necessitating disinfecting bathrooms, walls, and furniture. These areas possess large surface areas and, therefore, need a highly large quantity of disinfectants for their cleaning.

In 2022, the WHO reported that for every 100 acute care patients in high-income countries, seven high-income-country patients and 15 low- and middle-income-country patients will develop at least one HAI while in hospital. Considering the key contribution of contaminated surfaces to pathogen spread, increasing HAIs represent a growing call for effective surface disinfection techniques within healthcare to prevent infection transmission and promote patient safety.

The hospitals, clinics, and ASCs segment accounted for the largest market share in 2024 in the surface disinfectant market.

Based on end user, the surface disinfectant market is segmented into hospitals, clinics, and ASCs, diagnostic laboratories, pharmaceutical & biotechnology companies, and research laboratories. In 2024, the hospitals, clinics, and ASCs accounted for the largest market share in the surface disinfectant market. The large share of this segment can be attributed to the high prevalence of HAIs in hospitals and ASCs, stringent regulations for disinfection, and rising healthcare expenditure.

According to an article in NIH 2023, HAIs affect 3.2% of all hospitalized patients in the US and 6.5% in the European Union/European Economic Area, while in low- and middle-income countries, the prevalence rate ranges between 5.7% and 19.2%. The Centers for Disease Control and Prevention (CDC, 2022) estimated that in American hospitals, HAIs account for an estimated 1.7 million infections and 90,000 associated deaths each year. The high incidence of HAIs and the resulting cost burden on all the stakeholders have driven the adoption of infection prevention measures, such as disinfection and sterilization services, for their use in medical devices.

Europe accounted for the second-largest share of the surface disinfectant market by region in 2024.

The global surface disinfectant market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The surface disinfectant market in Europe in 2024 is the second-largest regional market. The rising prevalence of HAIs, the growing geriatric population, the increasing number of government initiatives for sterilization and disinfection, and the increasing presence of several disinfection and sterilization market players in the region are the major factors driving the surface disinfectant market in Europe. Germany accounted for the largest share of the surface disinfectant market in Europe.

The rapidly growing aging population, the increasing demand for healthcare services, the rising number of advancements in medical sciences, and rising life expectancies are also expected to result in an increasing number of surgical procedures performed yearly. According to the UN Population Division, Germany's population aged 65 and above is expected to rise by 41% to around 24 million by 2050, accounting for around 30% of the total population. This, in turn, will increase the number of spinal, orthopedic, and cardiovascular procedures performed, thereby driving the growth of HAIs and increasing the demand for surface disinfectants in Germany.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1- 40%, Tier 2- 30%, and Tier 3- 30%
• By Designation: C Level- 27%, Director Level- 18% and Others- 55%
• By Region: North America- 35%, Europe- 30%, Asia Pacific- 22%, Latin America- 10%, and Middle East & Africa- 3%

Note 1: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the surface disinfectant market are Reckitt Benckiser (UK), Procter & Gamble (US), 3M (US), Ecolab (US), The Clorox Company (US), STERIS (US), SC Johnson Professional USA, Inc. (US), CarrollCLEAN (US), Paul Hartmann AG (Germany), Medalkan (Greece), GOJO Industries, Inc. (US), Whiteley (Australia), Sanosil AG (Switzerland), Betco (US), Metrex Research, LLC. (US), KCWW (US), Acuro Organics Limited (India), Pharmax Limited (Canada), PDI, Inc. (US), CARENOW (India), Cetylite, Inc. (US), Micro-Scientific, LLC (US), Pal International (UK), Brulin (US), Amity International (UK), Wexford Labs, Inc. (US), Detrox (Turkiye), and Ruhof (US).

Research Coverage

This report studies the surface disinfectant market based on composition, type, application, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends. It forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

This report provides insights on the following pointers:

• Analysis of Key drivers (Growing focus on mitigating hospital-acquired infections, rising adoption of advanced surface disinfectants for sanitization, growing consumer awareness of hygiene in healthcare settings, and increasing surgical procedures), restraints (Potential consequences of chemical disinfectant use, increasing adoption of alternative surface disinfection methods), challenge (Strict regulatory requirements), opportunity (Rising healthcare expenditures in emerging economies, shift toward eco-friendly & non-toxic disinfectants, increasing presence of medical device and pharmaceutical companies in developing countries)
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the surface disinfectant market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the surface disinfectant market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the surface disinfectant market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 UNIT CONSIDERED
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources for secondary data
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Company revenue estimation approach
      • 2.2.1.1.1 Presentations of companies and primary interviews
      • 2.2.1.1.2 Primary interviews
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ANALYSIS
• 2.5 RESEARCH ASSUMPTIONS
  • 2.5.1 PARAMETRIC ASSUMPTIONS
  • 2.5.2 GROWTH RATE ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 SURFACE DISINFECTANT MARKET OVERVIEW
• 4.2 ASIA PACIFIC SURFACE DISINFECTANT MARKET, BY TYPE AND COUNTRY
• 4.3 SURFACE DISINFECTANT MARKET, BY COUNTRY
• 4.4 SURFACE DISINFECTANT MARKET, REGIONAL MIX, 2025 VS. 2030
• 4.5 SURFACE DISINFECTANT MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing focus on mitigating hospital-acquired infections
    • 5.2.1.2 Rising adoption of advanced surface disinfectants for sanitization
    • 5.2.1.3 Growing consumer awareness of hygiene in healthcare settings
    • 5.2.1.4 Increasing surgical procedures worldwide
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Potential consequences of chemical disinfectant use
    • 5.2.2.2 Increasing adoption of alternative surface disinfection methods
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Rising healthcare expenditure in emerging economies
    • 5.2.3.2 Shift toward eco-friendly and non-toxic disinfectants
    • 5.2.3.3 Increasing presence of medical device and pharmaceutical companies in developing countries
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Strict regulatory requirements
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
  • 5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Surface disinfection
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 UV disinfection
• 5.10 PATENT ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA FOR HS CODE 380894
  • 5.11.2 EXPORT DATA FOR HS CODE 380894
• 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.13 REGULATORY LANDSCAPE
  • 5.13.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.13.2 REGULATORY JURISDICTION
  • 5.13.3 REGULATORY ANALYSIS
    • 5.13.3.1 North America
      • 5.13.3.1.1 US
      • 5.13.3.1.2 Canada
    • 5.13.3.2 Europe
    • 5.13.3.3 Asia Pacific
      • 5.13.3.3.1 Japan
      • 5.13.3.3.2 India
      • 5.13.3.3.3 China
    • 5.13.3.4 Latin America
      • 5.13.3.4.1 Brazil
      • 5.13.3.4.2 Mexico
    • 5.13.3.5 Middle East
    • 5.13.3.6 Africa
• 5.14 PORTER'S FIVE FORCES ANALYSIS
  • 5.14.1 BARGAINING POWER OF BUYERS
  • 5.14.2 BARGAINING POWER OF SUPPLIERS
  • 5.14.3 THREAT OF NEW ENTRANTS
  • 5.14.4 THREAT OF SUBSTITUTES
  • 5.14.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.15.2 KEY BUYING CRITERIA
• 5.16 IMPACT OF AI/GEN AI ON SURFACE DISINFECTANT MARKET
  • 5.16.1 INTRODUCTION
  • 5.16.2 MARKET POTENTIAL OF AI IN SURFACE DISINFECTANT MARKET
  • 5.16.3 AI USE CASES
  • 5.16.4 FUTURE OF GENERATIVE AI IN SURFACE DISINFECTANT ECOSYSTEM

6 SURFACE DISINFECTANT MARKET, BY COMPOSITION

• 6.1 INTRODUCTION
• 6.2 ALCOHOLS
  • 6.2.1 INCREASING DEMAND FOR DOMESTIC AND HOSPITAL-GRADE DISINFECTANTS TO SUSTAIN GROWTH
• 6.3 CHLORINE COMPOUNDS
  • 6.3.1 MINIMAL ENVIRONMENTAL HAZARDS TO AMPLIFY GROWTH
• 6.4 QUATERNARY AMMONIUM COMPOUNDS
  • 6.4.1 ENHANCED RESIDUAL ACTIVITY AND BROAD-SPECTRUM EFFICACY TO STIMULATE GROWTH
• 6.5 HYDROGEN PEROXIDE
  • 6.5.1 LOW TOXICITY AND STRONG OXIDIZING PROPERTIES TO SUPPORT GROWTH
• 6.6 PERACETIC ACID
  • 6.6.1 WIDE USE AS DISINFECTANT, SANITIZER, BLEACH, STERILANT, INDUSTRIAL REAGENT, OXIDIZER, AND POLYMERIZATION CATALYST TO DRIVE MARKET
• 6.7 PHENOLIC COMPOUNDS
  • 6.7.1 RISING FOCUS ON LONG-LASTING INFECTION CONTROL TO FACILITATE GROWTH
• 6.8 OTHER COMPOSITIONS

7 SURFACE DISINFECTANT MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 LIQUIDS
  • 7.2.1 COST-EFFECTIVENESS AND HIGH EFFICACY TO ENCOURAGE GROWTH
• 7.3 WIPES
  • 7.3.1 ALCOHOL-BASED WIPES
    • 7.3.1.1 Stringent infection prevention protocols to contribute to growth
  • 7.3.2 QUATERNARY AMMONIUM COMPOUND-BASED WIPES
    • 7.3.2.1 Need for efficient, ready-to-use disinfection solutions in medical environment to expedite growth
  • 7.3.3 OTHER WIPES
• 7.4 SPRAYS
  • 7.4.1 GROWING USE OF SPRAYS IN FOGGING TECHNIQUES TO FUEL MARKET

8 SURFACE DISINFECTANT MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 SURFACE DISINFECTION
  • 8.2.1 INCREASING PREVALENCE OF HEALTHCARE-ASSOCIATED INFECTIONS TO AUGMENT GROWTH
• 8.3 INSTRUMENT DISINFECTION
  • 8.3.1 GROWING USE OF MEDICAL DEVICES IN HOSPITALS AND LABORATORIES TO DRIVE MARKET
• 8.4 OTHER APPLICATIONS

9 SURFACE DISINFECTANT MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS, CLINICS, AND ASCS
  • 9.2.1 GROWING FOCUS ON HOSPITAL HYGIENE TO BOOST MARKET
• 9.3 DIAGNOSTIC LABORATORIES
  • 9.3.1 NEED TO ENSURE COMPLIANCE WITH SAFETY AND REGULATORY STANDARDS TO AID GROWTH
• 9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.4.1 INCREASING FUNDING AND INVESTMENT ACTIVITIES IN PHARMA AND BIOTECH SECTOR TO PROMOTE GROWTH
• 9.5 RESEARCH LABORATORIES
  • 9.5.1 GROWING EMPHASIS ON STERILE AND CONTROLLED RESEARCH LABORATORY ENVIRONMENTS TO FUEL MARKET

10 SURFACE DISINFECTANT MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Rapid growth in geriatric population to encourage growth
  • 10.2.3 CANADA
    • 10.2.3.1 High prevalence of healthcare-associated infections to aid growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 High prevalence of HAIs in hospitals and ICUs to support market growth
  • 10.3.3 FRANCE
    • 10.3.3.1 Favorable insurance and infection control policies to accelerate growth
  • 10.3.4 UK
    • 10.3.4.1 Increasing funding for clinical trials to amplify growth
  • 10.3.5 ITALY
    • 10.3.5.1 Increasing geriatric population to favor growth
  • 10.3.6 SPAIN
    • 10.3.6.1 Growing prevalence of diabetes to drive market
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Changing lifestyles and prevalence of obesity to bolster growth
  • 10.4.3 JAPAN
    • 10.4.3.1 Universal healthcare coverage to contribute to growth
  • 10.4.4 INDIA
    • 10.4.4.1 Expanding acute care settings to fuel market
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Growing rate of chronic diseases to boost market
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Increasing focus on improving healthcare infrastructure to expedite growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Increased surgical procedures to support growth
  • 10.5.3 MEXICO
    • 10.5.3.1 Favorable government initiatives to augment growth
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 RISING HEALTHCARE EXPENDITURE AND ROBUST INFRASTRUCTURE DEVELOPMENT TO EXPEDITE GROWTH
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SURFACE DISINFECTANT MARKET
• 11.3 REVENUE ANALYSIS, 2019-2023
• 11.4 MARKET SHARE ANALYSIS, 2024
• 11.5 COMPANY VALUATION AND FINANCIAL METRICS
• 11.6 BRAND/PRODUCT COMPARISON
• 11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.7.1 STARS
  • 11.7.2 EMERGING LEADERS
  • 11.7.3 PERVASIVE PLAYERS
  • 11.7.4 PARTICIPANTS
  • 11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.7.5.1 Company footprint
    • 11.7.5.2 Region footprint
    • 11.7.5.3 Type footprint
    • 11.7.5.4 Application footprint
• 11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.8.1 PROGRESSIVE COMPANIES
  • 11.8.2 RESPONSIVE COMPANIES
  • 11.8.3 DYNAMIC COMPANIES
  • 11.8.4 STARTING BLOCKS
  • 11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 11.8.5.1 Detailed list of key startup/SME players
    • 11.8.5.2 Competitive benchmarking of key startups/SMEs
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES
  • 11.9.2 DEALS
  • 11.9.3 EXPANSIONS
  • 11.9.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 RECKITT BENCKISER
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Deals
      • 12.1.1.3.2 Expansions
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Right to win
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 PROCTER & GAMBLE
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 MnM view
      • 12.1.2.3.1 Right to win
      • 12.1.2.3.2 Strategic choices
      • 12.1.2.3.3 Weaknesses and competitive threats
  • 12.1.3 3M
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 MnM view
      • 12.1.3.3.1 Right to win
      • 12.1.3.3.2 Strategic choices
      • 12.1.3.3.3 Weaknesses and competitive threats
  • 12.1.4 THE CLOROX COMPANY
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Deals
  • 12.1.5 ECOLAB
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
  • 12.1.6 STERIS
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
  • 12.1.7 PAUL HARTMANN AG
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Product launches
  • 12.1.8 SC JOHNSON PROFESSIONAL USA, INC.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product launches
  • 12.1.9 CARROLLCLEAN
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
  • 12.1.10 MEDALKAN
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Product launches
  • 12.1.11 GOJO INDUSTRIES, INC.
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Product launches
  • 12.1.12 WHITELEY
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Other developments
  • 12.1.13 SANOSIL AG
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
  • 12.1.14 BETCO
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
  • 12.1.15 METREX RESEARCH, LLC
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
• 12.2 OTHER PLAYERS
  • 12.2.1 ACURO ORGANICS LIMITED
  • 12.2.2 PHARMAX LIMITED
  • 12.2.3 PDI, INC.
  • 12.2.4 RUHOF
  • 12.2.5 CARENOW
  • 12.2.6 CETYLITE, INC.
  • 12.2.7 MICRO-SCIENTIFIC, LLC
  • 12.2.8 PAL INTERNATIONAL
  • 12.2.9 BRULIN
  • 12.2.10 KCWW
  • 12.2.11 AMITY INTERNATIONAL
  • 12.2.12 WEXFORD LABS, INC.
  • 12.2.13 DETROX

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS